Mumps

EasiBuy to Exhibit at NIGP Forum 2022, Co-Founder Ben Koberna to Speak on Procurement Modernization

Retrieved on: 
Thursday, August 18, 2022
Technology, Human Resources, Professional Services, Public Policy, Government, Business, Software, Networks, State, Local, Outsourcing Business, Other Professional Services, LAPO, Counsel, Multimedia, Polio, Boston Convention and Exhibition Center, Technology, Osgoode Hall Law School, HPV, National Institute, DPT vaccine, Environment, Government, Federal Property and Administrative Services Act of 1949, Mumps, COVID-19, Fever Dream, MFP, Program, State, Innovation, Rubella, Vaccine, Secretary of State of South Carolina, Convention center, Rabies, Measles, Tetanus, Efficiency, City, Hepatitis B, Disease, Lojong, Nightclub, Auction

(Photo: Business Wire)

Key Points: 
  • (Photo: Business Wire)
    On Aug. 22, at 1:00 pm in The Innovation Theater, Koberna will present Procurement Mind Training, an interactive program designed to help professionals hone the leadership skills necessary to navigate the procurement modernization journey.
  • Koberna has been shaping the nature of reverse auction practice in the government setting since 2007.
  • EasiBuy will also be present throughout the event as an exhibitor and can be found at booth #625 in the events Exhibit Hall.
  • Forum 2022 will be held in Boston from Aug. 20-24 at the Boston Convention and Exhibition Center.

Illinois Residents Can Help Play Critical Role in Protecting Local Communities by Scheduling Immunizations

Retrieved on: 
Wednesday, August 17, 2022
Risk, Influenza, Caregiver, Hepatitis, Mumps, CDC, Vaccine-preventable diseases, COVID-19, School, Rubella, Parent, Vaccine, Infection, Immunization, Vaccination, Public health, Meridian Health Plan Headquarters, Tetanus, Illinois Department of Public Health, Student, Health, Measles, Illinois Department of Human Services, Health insurance, Meridian

Meridian Health Plan of Illinois (Meridian) is dedicated to ensuring Illinois residents have access to information and resources about routine immunizations to help protect children and communities against preventable illnesses.

Key Points: 
  • Meridian Health Plan of Illinois (Meridian) is dedicated to ensuring Illinois residents have access to information and resources about routine immunizations to help protect children and communities against preventable illnesses.
  • Amid the COVID-19 pandemic, immunizations have declined, with all populations showing a downward trend from pre-pandemic routine immunization rates .
  • Routine vaccinations have proven effective in preventing serious illness within schools and communities.
  • Immunizations not only protect the individuals who are vaccinated, they also protect everyone who interacts with them.

SINOVAC COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong Kong

Retrieved on: 
Wednesday, August 3, 2022
Biotechnology, Pharmaceutical, General Health, Health, COVID-19, Children, Infectious Diseases, Consumer, NASDAQ, Vaccine, Safety, Foot-and-mouth disease virus, Minor, Department, R, Program, Center, Health Bureau, H5N1, WHO, Scientific Committee on Antarctic Research, Infection, HFMD, Sinovac Biotech, Mumps, III, Scientific Committee on Emerging and Newly Identified Health Risks, Polio, Chickenpox, Hepatitis A, COVID-19, CoronaVac, Company, EV71, Carrie Lam as Chief Executive of Hong Kong, Vaccination, Streptococcus, COVID-19 vaccine, Ageing, Zoonosis, Influenza A virus subtype H1N1, Government

The vaccination schedule for this age group follows the same vaccination schedule of older children.

Key Points: 
  • The vaccination schedule for this age group follows the same vaccination schedule of older children.
  • SINOVAC initiated its COVID-19 vaccine (CoronaVac) phase III clinical studies among children aged 6 months to 17 years since 2021.
  • Preliminary results show the vaccine has a good safety and immunogenicity profile, with no severe adverse reaction reported 6 months after two doses of vaccination among children aged 6 months to 35 months.
  • SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities.

Takeda Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial Evaluating HYQVIA® for Maintenance Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Retrieved on: 
Thursday, July 21, 2022
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Vaccine, Patient, Diagnosis, Antibody, INCAT, Edema, Takeda Pharmaceutical Company, Adult, Safety, Genetics, Erythema, Product, Hematology, Clinical trial, Rubella, CIDP, Projection, Infection, IVIG, Acquisition, Investment, ADL, Primary immunodeficiency, U.S. Securities and Exchange Commission, Mumps, Union, Progressive inflammatory neuropathy, Itch, TAK, Chronic inflammatory demyelinating polyneuropathy, Advertising, Recombinant, Pain, Measles, Prevalence, SID, Fatigue, Immunoglobulin G, International Classification of Functioning, Disability and Health, Quality of life, Nausea, Peripheral nervous system, Annual report, Vomiting, R, Immunodeficiency, Maintenance, Headache, PI, Research and development, Chickenpox, SC, Medical device, Pharmaceutical industry, Gastroenterology, Fever, Takeda, Neuroscience

Takeda ( TSE:4502/NYSE:TAK ) today announced that ADVANCE-1, a randomized, placebo-controlled, double-blind Phase 3 clinical trial evaluating HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] for the maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), met its primary endpoint.

Key Points: 
  • Takeda ( TSE:4502/NYSE:TAK ) today announced that ADVANCE-1, a randomized, placebo-controlled, double-blind Phase 3 clinical trial evaluating HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] for the maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), met its primary endpoint.
  • Of the 62 patients treated with HYQVIA, the majority of treatment-related adverse events were reported as mild or moderate.
  • ADVANCE-1 was a Phase 3, multicenter, placebo-controlled, double-blinded study to evaluate the efficacy, safety and tolerability of HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] as a maintenance therapy to prevent relapse in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
  • Some of the secondary endpoints included time to relapse, effect on activities of daily living (ADL), safety and tolerability.

SINOVAC Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile

Retrieved on: 
Tuesday, July 19, 2022
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Clinical Trials, Influenza A virus subtype H1N1, III, Chickenpox, Volunteering, Infection, WHO, Safety, Republic, Polio, Foot-and-mouth disease virus, Program, EV71, PI, NASDAQ, Sinovac Biotech, COVID-19, Company, Hepatitis A, Ageing, Mumps, Streptococcus, H5N1, Vaccine, Clinical trial, HFMD, R, Coro de la Pontificia Universidad Católica de Puerto Rico

This clinical trial aims to evaluate the immunogenicity and safety of the quadrivalent influenza vaccine among individuals aged 3 and above.

Key Points: 
  • This clinical trial aims to evaluate the immunogenicity and safety of the quadrivalent influenza vaccine among individuals aged 3 and above.
  • In total, there will be 1,600 volunteers recruited, half of whom will receive 1 dose of SINOVACs inactivated quadrivalent influenza vaccine, and the other half will receive a different quadrivalent influenza vaccine commercially available in Chile.
  • Children aged between 3 and 8 of both groups who havent received any influenza vaccine will receive 2 doses of influenza vaccine.
  • The upcoming clinical trial in Chile will provide further evidence on the efficacy and safety of SINOVACs quadrivalent influenza vaccine.

SINOVAC COVID-19 Vaccine Is Authorized for Emergency Use in Kids Aged 3-5 In Brazil

Retrieved on: 
Thursday, July 14, 2022
COVID-19, Research, Infectious Diseases, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, COVID-19, Influenza A virus subtype H1N1, Program, Pulmonology, Vaccine, H5N1, Infection, HFMD, SBP, WHO, Vaccination, Company, Hepatitis A, R, Mumps, Foot-and-mouth disease virus, Ageing, Brazilian Association of Investigative Journalism, Minor, SBI, Chickenpox, Instituto Butantan, Sinovac Biotech, Research, Association, CoronaVac, EV71, Streptococcus, To Brazil!, NASDAQ, Polio, Pharmaceutical industry, Brazilian Health Regulatory Agency, COVID-19, Research, Infectious Diseases, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science

This authorization was given under comprehensive evaluations based on analysis results from all available data on the vaccine and its use in children.

Key Points: 
  • This authorization was given under comprehensive evaluations based on analysis results from all available data on the vaccine and its use in children.
  • To assist Anvisa in evaluating the vaccine, the experts from the above institutions had access to technical materials and research data on the vaccine.
  • CoronaVac has been authorized for emergency use for adults in Brazil since January 17, 2021.
  • SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities.

SINOVAC joins hands with HKU-CTC research team and Gleneagles Hospital Hong Kong to kick off a clinical trial of an Omicron-specific inactivated vaccine for booster use in Hong Kong, China

Retrieved on: 
Monday, July 4, 2022
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Department, Pharmacy and Poisons Board, Pharmacy, Influenza A virus subtype H1N1, School, Admission, CEO, RNA transfection, Adult, Research, GHK, Trial of the century, Polio, Li Ka Shing Faculty of Medicine, Wong Chuk Hang, Infection, COVID-19, Immunization, Â, Sinovac Biotech, Department of Medicine – University of Pamplona, HKU, Omicron, School of Clinical Medicine, University of Cambridge, LKS, Viral hepatitis, Asia-Pacific, Campus Biotech, IHH Healthcare, Poison, Clinical trial, NWS Holdings, University, IRB, Virus, Pyaar Tune Kya Kiya (TV series), Animal, Vaccine, Chickenpox, Safety, University of Hong Kong, Vaccination, EV71, Immunity, Faculty, Mumps, Bed, Multimedia, International business, Volunteering, Pharmaceutical industry, Medicine, Gleneagles Hospital

This study is led by a medical research team of the University of Hong Kong Clinical Trials Centre (HKU-CTC) in collaboration with Gleneagles.

Key Points: 
  • This study is led by a medical research team of the University of Hong Kong Clinical Trials Centre (HKU-CTC) in collaboration with Gleneagles.
  • The University of Hong Kong Clinical Trials Centre (HKU-CTC) is a one-stop clinical research management platform dedicated to facilitating the professional conduct of clinical research projects under HKUMed.
  • As Hong Kongs top-notch private teaching hospital, Gleneagles also contributes to the training and development of healthcare professionals and advancement of clinical research.
  • Gleneagles is a joint venture between IHH Healthcare and NWS Holdings Limited, with The University of Hong Kong as its exclusive clinical partner.

SINOVAC COVID-19 Vaccine Is Conditionally Registered In South Africa

Retrieved on: 
Saturday, June 25, 2022
Biotechnology, Pharmaceutical, Health, COVID-19, Influenza A virus subtype H1N1, Research, SAHPRA, Chinese government award for outstanding self finance students abroad, Polio, COVID-19, South African Health Products Regulatory Authority, Company, Hepatitis A, Hepatitis, Ageing, Infection, H5N1, Streptococcus, Sinovac Biotech, Risk management, Foot-and-mouth disease virus, NASDAQ, Vaccine, HFMD, Chickenpox, Safety, Mumps, EV71, WHO, Pharmaceutical industry

All the evidence suggested that the SINOVAC COVID-19 vaccine was safe and effective.

Key Points: 
  • All the evidence suggested that the SINOVAC COVID-19 vaccine was safe and effective.
  • SINOVAC COVID-19 vaccine has been available in more than 60 countries, with a total supply of almost 2.9 billion doses.
  • Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the research, development, manufacturing, and commercialization of vaccines that protect against human infectious diseases.
  • SINOVAC has been continually dedicating itself to new vaccine research and development, with more combination vaccine products in the pipeline, and constantly exploring opportunities in the international market.

SINOVAC Polio Vaccine Prequalified by WHO

Retrieved on: 
Thursday, June 9, 2022
Infectious Diseases, Biotechnology, Pharmaceutical, Health, GPEI, World Health Organization, UN, Polio, OPV, Global Polio Eradication Initiative, Research, Food, Immunization, Infection, Influenza A virus subtype H1N1, United Nations, Poliovirus, VAPP, Polio eradication, Sinovac Biotech, Mouth, Environment, Hepatitis A, Pain, WHO, Fever, Chickenpox, Motor neuron, Vaccine, Feces, Campus Biotech, Saliva, COVID-19, NASDAQ, Prevalence, CoronaVac, Water, Public health, Mumps, Profile, EV71, World

The vaccine will be available for United Nations (UN) agencies to purchase to support the global polio endgame strategy.

Key Points: 
  • The vaccine will be available for United Nations (UN) agencies to purchase to support the global polio endgame strategy.
  • The vaccine can be used sequentially with oral polio attenuated live vaccine (OPV).
  • With the impact of the global COVID-19 pandemic, countries where wild polio strains still exist have experienced an increasing prevalence of polio cases.
  • SINOVAC has been continually dedicating itself to new vaccine research and development, with more combined and new technology vaccine products in the pipeline.

GSK announces US FDA approval of PRIORIX for the prevention of measles, mumps and rubella in individuals 12 months of age and older

Retrieved on: 
Monday, June 6, 2022
Public Policy, Government, FDA, Health, Infectious Diseases, Public Policy, General Health, Mumps, Vaccination, Irritability, Association, Immunodeficiency, Rubella vaccine, Vaccine, Thrombocytopenia, Company, ACIP, US Foods, National Center for Immunization and Respiratory Diseases, Food, Contraindication, Thrombocytopenic purpura, Syringe, Annual report, Anaphylaxis, Symptoms of COVID-19, MMR, Pain, CDC, Senior, Fever, Red, Allergy, FDA, Patient, Disease, Mortality, Risk, Syncope, COVID-19, Green Cross (South Korean company), Febrile seizure, Vaccine-preventable diseases, MD, Clinical trial, Pregnancy, GSK, Rubella, Degenerative disease, Stockholm Environment Institute US Center, Measles, Safety, Swelling, Pharmaceutical industry, Medicine

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved PRIORIX (Measles, Mumps and Rubella Vaccine, Live) for active immunisation for the prevention of measles, mumps and rubella (MMR) in individuals 12 months of age and older.

Key Points: 
  • GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved PRIORIX (Measles, Mumps and Rubella Vaccine, Live) for active immunisation for the prevention of measles, mumps and rubella (MMR) in individuals 12 months of age and older.
  • PRIORIX may be administered as a first dose, followed by a second dose of PRIORIX.
  • PRIORIX may also be administered as a second dose to individuals who have previously received the first dose of another MMR-containing vaccine.
  • The CDC recommends people get a MMR vaccine to protect against measles, mumps and rubella.